FIG 1.

Response to larotrectinib. A waterfall plot of the maximum change in the target lesion size (investigator assessment) with larotrectinib treatment is shown for 15 evaluable patients whose lung cancers harbored a TRK fusion. ^aTwo patients had CNS metastases included as target lesions with a 100% and 59% reduction observed by cycle 4, respectively. Each patient number refers to the same patient across all tables and figures. CR, complete response; INV, investigator; IRC, independent review committee; ORR, objective response rate; PD, progressive disease; PR, partial response; SD, stable disease; TRK, tropomyosin receptor kinase.